Clinical Trial

Efficacy of HellenCare in Early-Stage Alzheimer's Disease

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 8, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate whether HellenCare, a multicomponent nutraceutical, improves cognitive and functional outcomes in patients with early-stage Alzheimer's disease (AD). The investigators will compare changes in outcomes between the HellenCare group and the placebo group to determine if the intervention is effective and safe.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-19.
Trial Details
NCT Number NCT06895525
Lead Sponsor Peking University First Hospital
Conditions Alzheimer's Disease Dementia
Enrollment 60 participants
Start Date 2025-04-15
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-08